Given that more than 10.7 million cases have been reported for COVID-19, there have been 10 reported cases of COVID-19 patients with Guillain-Barré Syndrome so far—only two reported cases in ...

Given that more than 10.7 million cases have been reported for COVID-19, there have been 10 reported cases of COVID-19 patients with Guillain-Barre Syndrome so far—only two reported cases in the ...

(HealthDay)—Studies are beginning to show that, in rare cases, people with severe COVID-19 may develop the serious nervous system disorder known as Guillain-Barre syndrome.

A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus.

Sept. 24 (UPI) --People with COVID-19 may be at increased risk for developing Guillain-Barre syndrome, a study published Friday by the journal Brain found. Eleven of 49 patients with the rare ...

While there have been several reports of Guillain-Barré Syndrome following COVID-19, this is the first in which COVID-19 actually triggered a recurrence of the condition -- in a 54-year-old man ...

Researchers at Rutgers University have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barré syndrome, a rare and potentially deadly disorder in which the body’s i… ...

Guillain-Barr é syndrome is an acute polyneuropathy that is often preceded by infection or, occasionally, vaccination. Two patients in the Johnson & Johnson COVID-19 vaccine trial developed ...

There have been reported cases of Guillain-Barre in response to COVID-19 infections," Dr. Fred Davis, associate chair of the emergency medicine department at Northwell Health Long Island Jewish ...

Johnson & Johnson’s beleaguered Covid-19 vaccine may be associated with a small increased risk of Guillain–Barré syndrome, a rare but potentially serious neurological condition, federal ...

Guillain-Barre syndrome has gained attention due to a possible link with COVID-19. Experts what the disease is as well as causes, symptoms and treatment.

Sherry H-Y. Chou, University of Pittsburgh; Aarti Sarwal, Wake Forest University, and Neha S. Dangayach, Icahn School of Medicine at Mount Sinai The patient in the case report (let’s call him ...